Atlas hires for biotech team

The early-stage VC firm has appointed Timothy Wilson to the firm’s life sciences investment practice.

Atlas Ventures, the early-stage technology and life-sciences firm which splits its investments between Europe and the US, has made its second appointment in the past month with the announcement that Timothy Wilson is to join the firm as principal at the life sciences investment practice.

Prior to joining Atlas Venture, Wilson was a senior managing director at Bear Stearns International where he was responsible for the global biotechnology and European healthcare team based in London and New York. He has also held senior positions at SG Cowen Securities, UBS Securities and Hambrecht & Quist, where he built teams to cover both European and US stocks. Wilson will be responsible both for targeting investment opportunities and assisting in the development of portfolio companies

The appointment of Wilson, who will be based in London, follows the appointment in late August of Anil Khatod as venture principal. He is a former Nortel Networks chief strategy officer, who was hired to focus on the firm’s communications and IT investments.

Atlas Venture is investing its sixth international venture fund the Atlas Venture Fund VI, which was originally set up as a $970m fund, but was subsequently cut back by twelve per cent to reflect what the firm described as a lessening of opportunities and a drop in valuations. The firm currently manages $2.4bn of committed capital.